Park Ha Biological Technology Co., Ltd. Financial Summary

Quick Answer

Park Ha Biological Technology Co., Ltd. reported Total Revenue of $2.52 million for fiscal year 2025.

Park Ha Biological Technology Co., Ltd. — Key Financials by Year

Metric 2025 2024 2023 2022 2021
Total Revenue $2.52M
+6.0%
$2.38M
-3.1%
$2.46M
+28.1%
$1.92M
Net Income -$24.36M
-5191.3%
$478.6K
-43.8%
$852.0K
+345.4%
$191.3K
Diluted EPS -$41.38
-4410.4%
$0.96
-43.5%
$1.70
+16900.0%
$0.01
Total Assets $5.95M
+93.1%
$3.08M
+36.1%
$2.26M
Cash and Equivalents $3.79M
+591.8%
$547.5K
-47.0%
$1.03M
Stockholders Equity $3.99M
+165.2%
$1.51M
+48.8%
$1.01M
+573.7%
$150.3K
+126.0%
-$578.2K
R&D Expense $238.2K
+548.8%
$36.7K
+18.9%
$30.9K
-49.1%
$60.7K
Operating Income -$24.15M
-3142.5%
$793.7K
-32.8%
$1.18M
+499.2%
$197.0K
Gross Profit $2.38M
+9.0%
$2.19M
+1.8%
$2.15M
+52.3%
$1.41M
Shares Outstanding 25.00M
+0.0%
25.00M
  • Park Ha Biological Technology Co., Ltd. reported Total Revenue of $2.52 million for fiscal year 2025.
  • Park Ha Biological Technology Co., Ltd. showed an increase of +6.0% in Total Revenue compared to the prior fiscal year.
  • Park Ha Biological Technology Co., Ltd. reported Net Income of -$24.36 million for fiscal year 2025.
  • Park Ha Biological Technology Co., Ltd. showed a decrease of -5191.3% in Net Income compared to the prior fiscal year.
  • Park Ha Biological Technology Co., Ltd. reported Diluted EPS of $41.38 per share (loss) for fiscal year 2025.
  • Park Ha Biological Technology Co., Ltd. showed a decrease of -4410.4% in Diluted EPS compared to the prior fiscal year.
  • Park Ha Biological Technology Co., Ltd. reported Total Assets of $5.95 million for fiscal year 2025.
  • Park Ha Biological Technology Co., Ltd. showed an increase of +93.1% in Total Assets compared to the prior fiscal year.
  • Park Ha Biological Technology Co., Ltd. reported Cash and Equivalents of $3.79 million for fiscal year 2025.
  • Park Ha Biological Technology Co., Ltd. showed an increase of +591.8% in Cash and Equivalents compared to the prior fiscal year.
  • Park Ha Biological Technology Co., Ltd. reported Stockholders Equity of $3.99 million for fiscal year 2025.
  • Park Ha Biological Technology Co., Ltd. showed an increase of +165.2% in Stockholders Equity compared to the prior fiscal year.
  • Park Ha Biological Technology Co., Ltd. reported R&D Expense of $238.2 thousand for fiscal year 2025.
  • Park Ha Biological Technology Co., Ltd. showed an increase of +548.8% in R&D Expense compared to the prior fiscal year.
  • Park Ha Biological Technology Co., Ltd. reported Operating Income of -$24.15 million for fiscal year 2025.
  • Park Ha Biological Technology Co., Ltd. showed a decrease of -3142.5% in Operating Income compared to the prior fiscal year.
  • Park Ha Biological Technology Co., Ltd. reported Gross Profit of $2.38 million for fiscal year 2025.
  • Park Ha Biological Technology Co., Ltd. showed an increase of +9.0% in Gross Profit compared to the prior fiscal year.
  • Park Ha Biological Technology Co., Ltd. reported Shares Outstanding of 25.00 million shares for fiscal year 2024.
  • Park Ha Biological Technology Co., Ltd. showed an increase of +0.0% in Shares Outstanding compared to the prior fiscal year.
  • All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.

Last verified:

Leave a Comment